Pennsylvania Medicaid coverage for Wegovy (Weight Loss)

Effective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of overweight or obesity for MA beneficiaries. The bulletin states: 'GLP-1 Receptor Agonists are not covered for the treatment of overweight or obesity.'

Policy note: Pennsylvania MA explicitly ended coverage of all GLP-1 receptor agonists for overweight/obesity effective January 1, 2026. Wegovy is non-preferred on the PDL; for non-diabetes indications it requires step through preferred agents. This entry covers the weight_loss exclusion only.

Policy effective January 1, 2026 · verified June 4, 2026 · source: mab2025112403.pdf